Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ireland prepares for healthcare reform:

This article was originally published in Clinica

Executive Summary

Ireland has launched a major audit of the healthcare system, ahead of a reform aimed at ensuring that it is in "the best position to deliver the goals of the new Health Strategy". The audit will consider how best to rationalise the system, to ensure that it is responsive to current and future needs, provides an adequate governance framework and effectively integrates all services. The overall structure of the interrelationship between the health boards and the new agencies, created to address the new needs and expectations, needs to be reviewed, said the department of health. The system has remained largely unchanged for 30 years, despite wide-ranging social change, it added. "The audit is of strategic significance in the roll-out of the Health Strategy and the reshaping of our health system," said minister Micheal Martin of the initiative. The audit report is due to be published in December 2002.

You may also be interested in...

HHS Policy Move Means FDA Must Publish More Documentation To Support Rulemaking Decisions

To be more transparent and allow more public discourse, the HHS now requires all its agencies to publish documents it uses to rationalize proposed rules and demonstration projects.

Dr Reddy's Strengthens Russian OTC Portfolio Through Glenmark Deal

Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from India's Glenmark.

Moderna Files COVID-19 Vaccine After Second Impressive Read-Out

Second read-out maintains 94% level of efficacy, with a very early signal that it could outperform Pfizer’s rival mRNA candidate in preventing severe cases.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts